bluuebunny/crossref_metadata_2025_split huggingface dataset:
Dietary Iron Increases Expression of Liver Hepcidin Relative to BMP6 By a Mechanism Involving Transferrin Receptor 2 and Specificity of Transferrin Lobe Iron Occupancy
Authors: Parrow Nermi , Ali Faris , George Nisha , Ginzburg Yelena , Rivella Stefano , Fleming Robert E 
Published: November 2021

Abstract
Introduction: Prior studies have identified two iron signals regulating liver hepcidin expression (PMID 21488083, 21480335). One is mediated by liver sinusoidal BMP6 (and BMP2) and is reflective of liver iron concentration (LIC). The other is independent of BMP expression and reflective of transferrin saturation. The mechanism by which TF regulates hepcidin is unclear but appears to involve hepatocellular transferrin receptor 2 (TFR2). We previously generated mice with TF mutations that block iron binding to either N-lobe (Tf N-bl) or C-lobe (Tf C-bl). These mice demonstrated differences in Epo sensitivity and hepcidin regulation (PMID 31434707). To characterize the differential regulation of Hamp1 in these mice we analyzed the effect of dietary iron in juvenile mice. This model advantages a physiologic low iron state with very low basal Hamp1 and Bmp6 expression.
Methods: Twelve-day old WT, Tf N-bl, Tf C-bland Tfr2 Y245X (functional knockout) mice were gavaged with 4 mg/kg/d FeSO 4 (or saline) in 2 divided doses for 3 days and sacrificed on the fourth day. The primary outcome was liver Hamp1 relative to Bmp6 expression by RT-PCR. Other iron-related parameters included liver Bmp2, serum and tissue non-heme iron, and TIBC. Erythroid parameters included splenic Fam132b (Erfe gene) expression, kidney Epo, blood packed cell volume (PCV), splenic weight index (SWI).
Results: Iron-treated mice demonstrated increased serum iron, TF saturation, LIC, liver Bmp6 in all strains compared to untreated. Liver Hamp1 was increased in all strains with iron-treatment; however, the magnitude was least in the Tf N-bland greatest in the Tf C-bl mice. Splenic Fam132b was unchanged. The iron-treated Tf C-bl had ~16 fold greater Hamp1 compared with iron-treated Tf N-bl mice (P=0.0005), despite similar Bmp6, Bmp2, and splenic Fam132b expression. The iron-treated Tf C-bl mice also had modestly higher splenic index and PCV compared with iron-treated Tf N-bl mice, despite similar kidney Epo. In Tfr2 Y245X mice Hamp1 and Hamp1 indexed to Bmp6 expression was intermediate between Tf N-bland Tf C-bl mice (figure).
Conclusion: Iron treatment increased liver Bmp6 expression as well as Bmp6 sensitivity (Hamp:Bmp6), in association with increases in LIC and in TF saturation. The effect of iron on Bmp6 sensitivity is markedly influenced by which TF lobe iron occupies, as well as the presence of TFR2. These observations support a model in which TF modulates the hepcidin response to BMP6 in either direction, via interaction with TFR2. We speculate that iron occupancy of the N-lobe of transferrin confers an upregulatory signal to hepcidin expression in the hepatocyte, and that its absence confers a downregulatory signal to BMP6 sensitivity in the hepatocyte.
Figure 1 Figure 1.

Disclosures
No relevant conflicts of interest to declare.
Impairment of Annexin A2-Mediated Cell Surface Fibrinolysis in Nonalcoholic Steatohepatitis Cirrhosis with Portal Vein Thrombosis
Authors: Lim Hana I. , Fortune Brett , Desancho Maria T. , Hajjar Katherine A. 
Published: November 2021

Abstract
The annexin A2 (A2) complex assembles tissue plasminogen activator and plasminogen on cell surfaces, resulting in efficient plasmin generation, and is markedly reduced in some patients with thrombophilia. Nonalcoholic steatosis (NASH) cirrhosis is the leading cause of cirrhosis in developed countries, and patients with NASH cirrhosis are at increased risk of portal vein thrombosis (PVT). However, the exact mechanism for PVT in NASH cirrhosis is poorly understood. Our objective was to determine the potential contribution of A2 to NASH thrombogenesis.
Using semiquantitative immunoblot analysis, we examined A2 expression in peripheral blood mononuclear cell (PBMC) lysates from obese controls and NASH subjects with or without cirrhosis, and in human umbilical vein endothelial cells (HUVECs) treated with platelet-poor plasma (PPP) from patients with varying degrees of NASH cirrhosis. We also analyzed formalin-fixed liver tissue from patients with or without steatosis or NASH cirrhosis for A2 expression by immunofluorescence. Finally, we evaluated A2-dependent PBMC surface plasmin generation using a fluorogenic assay, and systemic fluid-phase fibrinolysis via plasmin-anti-antiplasmin (PAP) complex and D-dimer ELISAs.
Total A2 expression in PBMC lysates did not differ among subjects with a range of severity of NASH cirrhosis versus obese controls. Src kinase-dependent tyrosine phosphorylation of A2, which is critical for its translocation to the cell surface, decreased in HUVECs after co-culture with NASH Child-Turcotte-Pugh C PPP despite no change in total A2. Immunofluorescence of liver tissue from patients with NASH cirrhosis who developed PVT revealed an 85% decrease in microvascular A2 expression compared to NASH cirrhosis patients without PVT. Similarly, PBMC surface plasmin generation decreased as NASH severity worsened, even though d-dimer and PAP complex level increased with worsening disease severity, indicating more activated systemic fibrinolysis in decompensated NASH cirrhosis.
Despite preservation of total A2 and acceleration of systemic fibrinolysis in NASH, A2-mediated cell surface fibrinolysis decreased as NASH cirrhosis worsened. We show for the first time that impaired A2-related fibrinolysis may reflect inhibition of A2 phosphorylation by NASH plasma, and that reduction of A2 expression in the hepatic microvasculature may contribute to PVT in these subjects.

Disclosures
Desancho: Sanofi-Genzyme: Membership on an entity's Board of Directors or advisory committees.
FGFR1 Fusion Genes Combine with RUNX1 Mutations to Drive Leukemogenesis
Authors: Wang Zheng , Wen Lijun , Chen Suning , Wu Depei 
Published: November 2021

Abstract
8p11 myeloproliferative syndrome is a myeloid tumor characterized by FGFR1 fusion gene. Its progression is fast, prognosis is bad and pathogenesis is not clear. We screened 10 cases of FGFR1 rearrangement (1 new fusion gene TFG-FGFR1), and 8 of them performed second generations of target exon capture and resequencing. The results showed that RUNX1 gene mutation occurred in 6 cases, with a mutation rate of 75%. The pretest results showed that FGFR1 fusion gene could significantly activate the downstream signaling pathway of FGFR1, and then promote cell proliferation, while RUNX1 gene mutation could block cell differentiation. It is presumed that FGFR1 gene fusion and RUNX1 mutation could lead to leukemia formation. Based on our previous work, we will explore the synergistic pathogenicity, the differences of variable opposite genes and possible mechanisms of FGFR1 fusion gene and RUNX1 mutation in vitro based on cell biology and animal models in vivo, and explore the therapeutic effect of targeted drugs in such diseases. This topic will help clarify the synergistic pathogenic effect of FGFR1 fusion gene and RUNX1 mutation and its related mechanisms, and provide theoretical and experimental evidence for the diagnosis and treatment of this disease.
Figure 1 Figure 1.

Disclosures
No relevant conflicts of interest to declare.
Plasma NTPDase1 Activity Regulates Platelet Purinergic Signaling in Sickle Cell Disease
Authors: Brzoska Tomasz , Menchikova Elizaveta V , Kaminski Tomasz W. , Vats Ravi , Tutuncuoglu Egemen , Tofovic Stevan P. , Jackson Edwin K. , Gladwin Mark T. , Sundd Prithu 
Published: November 2021

Abstract
Acute systemic painful vaso-occlusive episode (VOE) often serves as an antecedent to acute chest syndrome (ACS), which is a type of acute lung injury and the leading cause of mortality among sickle cell disease (SCD) patients. Based on clinical epidemiology, ACS is often preceded by thrombocytopenia and involves massive thrombosis across pulmonary artery branches in 10-20% of ACS patients. Although, released during hemolysis, adenosine diphosphate (ADP) is known to activate platelets by stimulating their P2Y1 and P2Y12 purinergic receptors, antagonists of P2Y12 have not shown any benefit in ACS therapy, justifying the need for better understanding of purinergic signaling in SCD. Ecto-nucleoside-tri-phosphate-diphosphohydrolase-1 (E-NTPDase1; CD39) maintains ADP homeostasis by degrading excessive ADP. Though CD39 inhibits ADP-dependent platelet activation and vascular thrombosis, its role in ASC is still unidentified.
Here, we use intravital lung microscopy in transgenic humanized SCD mice to show that intravascular (IV) administration of ADP triggered pulmonary thrombosis in control mice but failed to trigger pulmonary thrombosis in SCD mice. Identical to intravital findings, IV ADP administration also evoked transient thrombocytopenia in control but not SCD mice, while, IV collagen led to comparable drop in platelet count in both SCD and control mice. In vitro turbidimetric aggregation study yet again demonstrated impaired SCD mouse platelet response to ADP, which was significantly augmented by CD39 inhibitor (sodium metatungstate, POM-1). Indeed, we found significantly higher plasma levels and activity of CD39 in SCD mice compared to control mice using ELISA and malachite green assays, respectively. Hemin, a major host-derived damage associated molecular pattern (DAMP) in SCD, was incubated with Human Lung MicroVascular Endothelial Cell (HMVEC-L) to assess CD39 expression using western blotting. Hemin (10 -100 µM) in a dose dependent manner decreased CD39 levels in HMVEC-L.
Our current findings suggest that elevated CD39 plasma levels and activity possibly prevents ADP-mediated platelet aggregation and pulmonary thrombosis in SCD. We demonstrated that SCD milieu promotes loss of endothelial CD39, which may be directly associated with increased CD39 plasma levels and activity. Current study explains why P2Y12 blockers are not effective in SCD therapy and warrant the need for further studies to understand the role of purinergic signaling in pathogenesis of ACS.

Disclosures
Sundd: Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; CSL Behring Inc: Research Funding; Bayer: Research Funding.
Survival Trend of Waldenstrom Macroglobulinemia over Last 3 Decade Shows Health Disparities in Minority Population
Authors: Madhira Bhaskara Reddy , Durer Seren , Ghimire Krishna 
Published: November 2021

Abstract
Introduction:
Waldenstrom macroglobulinemia (WM) is a rare and incurable lymphoma. There have been significant changes in management of WM over last decade with incorporation of monoclonal antibodies, and other novel therapies. We conducted this study to evaluate survival rate among patients with WM.
Methods:
We selected patients with WM diagnosed during 1992-2018 from Surveillance, Epidemiology and End Results (SEER) 13 database. We analyzed 1- and 5-years relative survival (RS) rates using SEER*stat program. We used Z test to compare relative survival trend over 3 decades (1 st: 1992-2000, 2 nd: 2001-2010, 3 rd: 2011-2018) among patients with WM by race (white, other), age (&gt;18 years, 18-64 years and &gt;65 years) and sex.
Results:
A total of 5,690 (1,582; 2,141; and 1,967) adults patients were diagnosed with WM during 1992-2018 (1 st, 2 nd, and 3 rd decades), 86% were white and 14% were other races combined. There were 1,959 and 3,731 patients in age group (18-64 and &gt;65years) respectively. During 1 st, 2nd and 3 rd decades examined, 1 and 5 year RS in patients with WM were (87.3%, 92.0% and 94.7%) and (67.7%, 81.3%, and 85.7%) respectively. Improvement in RS was noted in both younger and older age group and sex examined. (Table 1)
White patients with WM have 1 and 5 year RS (87.3%, 92.6%, 95.1%) and (68.2%, 82.1%, 86.3%). This improvement RS over 3 decades was statistically significant with Z value &gt;1.65/P value &lt;0.05. Other races with WM have 1 and 5 year RS (86.5%, 86.9%, 90.4%) and (64.3%, 72.3%, 78.1%) during 1 st, 2nd and 3 rd decades.
Conclusion: This study showed that relative survival rates of WM have significantly improved over past 3 decades. Improvement in survival trend was mainly driven by white patients. Patients with other races do not have statistically significant improvement in relative survival rates during last 3 decades. Health disparities in minority population with WM warrants further research.
Figure 1 Figure 1.

Disclosures
No relevant conflicts of interest to declare.
Frequency and Survival of T-Cell Lymphomas in Peru: Initial Report of a Peruvian Registry Experience
Authors: Enriquez Daniel J , Casas Jhoisy , Sandival Gustavo , Espino Johan , Espinoza-Morales Evelyn , Cervantes Elizabeth , Castro-Mollo Melanie , Jiménez-Mozo Fátima , Dueñas Daniela , Barrionuevo Carlos , Haro Juan C , Ortega Emperatriz , Roque Katia , Vidaurre Tatiana , Lozano Sophia , Quintana Shirley , Vasquez Jule , Lopez Lourdes , Alcarraz Cindy , Diaz Alonso , Flores Claudio , Samanez-Figari Cesar 
Published: November 2021

Abstract
Introduction: T-cell lymphomas are a relatively rare and heterogeneous group of lymphoid neoplasms. Its incidence relies on viral infections incidence as Human T-cell lymphotropic virus type I-II (HTLV-I/II) and Ebstein Bar virus (EBV). Specifically, these viruses have a significantly higher incidence in Latin-American populations. Our objective was to calculate the incidence and survival of T-cell lymphomas in the largest Peruvian population based on a national registry. Methods: We conducted a multicenter, retrospective registry study of non-Hodgkin T cell lymphoma. The data was extracted from Instituto Nacional de Enfermedades Neoplasicas and Oncosalud-AUNA, Lima-Peru, from January 2010 to December 2019, a total of 948 patients who were diagnosed as mature T cell non-Hodgkin lymphoma based on the World Health Organization Classification 2008 were enrolled. T-lymphoblastic lymphoma/leukemia was excluded. Overall survival was calculated based on death dates from the Peruvian national identification registry (RENIEC).
Results: The median age was 51 years (range, 1-94), and male and female patients were 512 (54%) and 436 (46%). Among the 948 patients enrolled, Peripheral T-cell lymphoma was the common neoplasm accounting for 23% (n=221), and Extra-Nodal NK T-lymphoma (22%, n=213), Adult T-cell lymphoma (22%, n=205), Anaplasic Large cell lymphoma (14%, n=131), Cutaneous T-cell lymphoma (14%, n=129) (Figure 1a). At the time of diagnosis, extranodal disease was found in 68.6% (650) of patients. By July 2021, only 15.3% of cases were in remission and 37% (350) were alive. Median global overall survival of T-cell lymphomas was 1 year (0.8-1.1), Cutaneous T-cell lymphoma had the highest survival and Adult T-cell lymphoma had the lowest survival (Table 1 and Figure 1b).
Conclusion: This initial report shows a relatively high frequency of mature T-cell lymphomas in Latin-America real-world setting, and confirms that T-cell lymphomas patients had a dismal outcome. The clinical outcome for patients with T-cell lymphomas subtypes is poor with standard therapies, and novel agents and new modalities are needed to improve survival.
Figure 1 Figure 1.

Disclosures
No relevant conflicts of interest to declare.
Ing4-Deficiency Enhances Hematopoietic Stem Cell Quiescence and Confers Resistance to Inflammatory Stress
Authors: Thompson Zanshé , Anderson Georgina A , Gabriel Seth , Rodriguez Melanie , Binder Vera , Kathrein Katie L 
Published: November 2021

Abstract
In a screen for epigenetic regulators of hematopoiesis in zebrafish, we identified a requirement of the tumor suppressor protein, Ing4, in hematopoietic stem and progenitor cell (HSPC) specification. Though the Ing4 mechanism of action remains poorly characterized, loss of Ing4 has been shown to promote stem cell-like characteristics in malignant cells and it is a frequent target of inactivation in various types of cancer. Mutations in Ing4 cause deregulation of both NF-kB and c-Myc target gene expression. We have also identified a requirement for Ing4 in murine hematopoiesis. Ing4-/- mice have aberrant hematopoiesis and elevated cytokine expression in bone marrow cells. Using RNA-sequencing, we found that Ing4-deficient HSPCs express high levels of c-Myc target genes and genes associated with oxidative phosphorylation and ribosomal biogenesis. Yet, Ing4 deficiency induces G 0 arrest in HSPCs and they have low levels of reactive oxygen species. This places Ing4-deficient HSPCs in a poised state, where they are quiescent, but express elevated levels of genes associated with differentiation. Under stress hematopoiesis following low-dose irradiation, Ing4-deficient long-term hematopoietic stem cells (LT-HSCs) do not expand, but short-term hematopoietic stem cells (ST-HSCs) function comparably to wild-type. Similarly, under transplantation stress, LT-HSCs fail to contribute to multilineage chimerism, while ST-HSCs contribute at levels equal to wild-type cells. These results are striking, particularly when compared to other models of enhanced NF-kB activity, where HSPCs cannot contribute to multilineage chimerism in transplantation. We sought to target the misregulated pathways in Ing4-deficient HSCs to rescue to effects of Ing4 deficiency. To this end, we chose to target the c-Myc pathway for several reasons: c-Myc target genes are over-represented in our RNA-seq data, c-Myc lies upstream of several of the misregulated pathways observed in Ing4-/- HSCs, and Ing4 has previously been reported to negatively regulate c-Myc activity directly. When treated with the c-Myc inhibitor, 10058-F4, both LT-HSCs and ST-HSCs are pushed into cycling, but this treatment also resulted in fewer cells overall. These results suggest that dampening of the c-Myc pathway can partially rescue Ing4 loss of function. Overall, our findings suggest that Ing4 plays a crucial role in the regulation of hematopoiesis and provides key tools for further identification and characterization of Ing4 pathways and functions. Given the role of Ing4 in both normal hematopoiesis and cancer, this gene likely has a critical role in regulation of stem cell self-renewal and maintenance.

Disclosures
No relevant conflicts of interest to declare.
Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient and Specific Genome Engineering for Cell Therapy Development
Authors: Cost Gregory J. , Lamothe Rebecca C. , Storlie Meghan D. , Rivas Andres , Espinosa Diego A. , Goltsman Daniela S. A. , Alexander Lisa , Butterfield Cristina N. , Brown Christopher T. , Thomas Brian C. 
Published: November 2021

Abstract
Gene-editing technology has revolutionized molecular therapeutics, enabling DNA-engineering-based approaches to treat disease. Despite this, development of medicines using gene editing has been hampered by technological, immunological, and legal limitations. We described previously the discovery of novel type II and type V gene-editing systems from metagenomic data, the characterization of these systems in vitro, and a demonstration of their activity in immortalized cell lines. Here, we substantially advance this work with three separate, novel gene-editing systems, demonstrating their utility for cell therapy development. We express and purify the nuclease components of both type II and type V effectors and show that all three systems are capable of reproducible, high-frequency gene editing in primary immune cells. In human T cells, disruption of the T cell receptor (TCR) alpha-chain constant region occurred in up to 95% of cells, both copies of the TCR beta-chain constant region in up to ~90% of cells, and beta-2 microglobulin in up to 95% of cells. Simultaneous double knock-out of TRAC and TRBC was obtained at an equal frequency. Gene editing with our systems had no effect on T cell viability. Further, we use our novel gene-editing systems to exploit homology-dependent DNA repair to integrate a CAR construct into the TCR alpha-chain locus (in up to ~60% of T cells), and demonstrate high-level CAR expression and antigen-dependent CAR-T cytotoxicity. Such robust editing activity at the TCR loci will permit efficient engineering and manufacture of allogeneic chimeric antigen receptor- (CAR) and TCR-based cell therapies.
We next applied our novel gene-editing tools to NK cells and B cells. We achieved almost 100% gene disruption at the CD38 locus in NK cells and integrated a chimeric antigen receptor into the NK cell genome at a frequency of ~40%. Such CAR-NK cells displayed robust CAR-directed cellular cytotoxicity. B cell editing occurred in approximately 80% of target cells with successful transgene integration.
Cas9 is notorious for tolerating mismatches and bulges in its target, resulting in high levels of unwanted DNA double-strand break formation. In contrast, interrogation of our gene editing systems using GUIDE-seq reveals no or very few off-target sites even at doses greatly in excess of those required for high-frequency gene editing. Finally, as our systems are taken from microbes found in environmental samples rather than from human pathogens, we expect pre-existing immunity to our nucleases will be quite rare. In all, we show that three new gene-editing systems have the activity, specificity, and translatability necessary for use in cell therapy development.

Disclosures
No relevant conflicts of interest to declare.
Machine learning approaches to predict the Plant-associated phenotype of Xanthomonas strains
Authors: te Molder Dennie , Poncheewin Wasin , Schaap Peter J. , Koehorst Jasper J. 
Published: November 2021

Abstract
Background
The genus Xanthomonas has long been considered to consist predominantly of plant pathogens, but over the last decade there has been an increasing number of reports on non-pathogenic and endophytic members. As Xanthomonas species are prevalent pathogens on a wide variety of important crops around the world, there is a need to distinguish between these plant-associated phenotypes. To date a large number of Xanthomonas genomes have been sequenced, which enables the application of machine learning (ML) approaches on the genome content to predict this phenotype. Until now such approaches to the pathogenomics of Xanthomonas strains have been hampered by the fragmentation of information regarding pathogenicity of individual strains over many studies. Unification of this information into a single resource was therefore considered to be an essential step.

Results
Mining of 39 papers considering both plant-associated phenotypes, allowed for a phenotypic classification of 578 Xanthomonas strains. For 65 plant-pathogenic and 53 non-pathogenic strains the corresponding genomes were available and de novo annotated for the presence of Pfam protein domains used as features to train and compare three ML classification algorithms; CART, Lasso and Random Forest.

Conclusion
The literature resource in combination with recursive feature extraction used in the ML classification algorithms provided further insights into the virulence enabling factors, but also highlighted domains linked to traits not present in pathogenic strains.